JP2004504406A5 - - Google Patents

Download PDF

Info

Publication number
JP2004504406A5
JP2004504406A5 JP2002514154A JP2002514154A JP2004504406A5 JP 2004504406 A5 JP2004504406 A5 JP 2004504406A5 JP 2002514154 A JP2002514154 A JP 2002514154A JP 2002514154 A JP2002514154 A JP 2002514154A JP 2004504406 A5 JP2004504406 A5 JP 2004504406A5
Authority
JP
Japan
Prior art keywords
ser
peptide
mammal
leu
pro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002514154A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004504406A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2001/007929 external-priority patent/WO2002008250A2/en
Publication of JP2004504406A publication Critical patent/JP2004504406A/ja
Publication of JP2004504406A5 publication Critical patent/JP2004504406A5/ja
Pending legal-status Critical Current

Links

JP2002514154A 2000-07-24 2001-07-10 グレリンアンタゴニスト Pending JP2004504406A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22017800P 2000-07-24 2000-07-24
PCT/EP2001/007929 WO2002008250A2 (en) 2000-07-24 2001-07-10 Ghrelin antagonists

Publications (2)

Publication Number Publication Date
JP2004504406A JP2004504406A (ja) 2004-02-12
JP2004504406A5 true JP2004504406A5 (enExample) 2005-02-17

Family

ID=22822394

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002514154A Pending JP2004504406A (ja) 2000-07-24 2001-07-10 グレリンアンタゴニスト

Country Status (9)

Country Link
US (1) US20020187938A1 (enExample)
EP (1) EP1303538A2 (enExample)
JP (1) JP2004504406A (enExample)
KR (1) KR20030033002A (enExample)
CN (1) CN1443198A (enExample)
AU (1) AU2001283938A1 (enExample)
CA (1) CA2416643A1 (enExample)
MX (1) MXPA03000738A (enExample)
WO (1) WO2002008250A2 (enExample)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1385879A4 (en) * 2001-05-10 2005-02-02 Univ Queensland DIAGNOSIS AND THERAPY OF CANCER OF REPRODUCTIVE ORGANS
US7105526B2 (en) 2002-06-28 2006-09-12 Banyu Pharmaceuticals Co., Ltd. Benzimidazole derivatives
US20040076645A1 (en) * 2002-07-19 2004-04-22 Bachmann Martin F. Ghrelin-carrier conjugates
RU2373220C2 (ru) * 2002-07-23 2009-11-20 Сосьете Де Консей Де Решерш Э Д`Аппликасьон Сьентифик (С.К.Р.А.С.) Аналоги грелина
TWI331922B (en) 2002-08-09 2010-10-21 Ipsen Pharma Sas Growth hormone releasing peptides
US20040121407A1 (en) * 2002-09-06 2004-06-24 Elixir Pharmaceuticals, Inc. Regulation of the growth hormone/IGF-1 axis
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
EP1648923B1 (en) * 2003-07-31 2008-12-31 Tranzyme Pharma Inc. Spatially-defined macrocycles incorporating peptide bond surrogates
US7452862B2 (en) 2003-07-31 2008-11-18 Tranzyme Pharma, Inc. Conformationally-controlled biologically active macrocyclic small molecules as motilin antagonists or ghrelin agonists
US20070275877A1 (en) * 2003-08-29 2007-11-29 Amylin Pharmaceuticals, Inc. Methods for Treating or Ameliorating Ghrelin-Associated Diseases and Disorders
WO2005028438A1 (ja) 2003-09-22 2005-03-31 Banyu Pharmaceutical Co., Ltd. 新規ピペリジン誘導体
DE602004012207T2 (de) * 2003-10-16 2009-03-12 F. Hoffmann-La Roche Ag Fluoreszent markierte Ghrelin-Peptide
EP1734963A4 (en) 2004-04-02 2008-06-18 Merck & Co Inc METHOD FOR TREATING PEOPLE WITH METABOLIC AND ANTHROPOMETRIC DISORDER
JP2007537207A (ja) * 2004-05-14 2007-12-20 ノボ ノルディスク アクティーゼルスカブ 一定の中枢神経疾患の治療のためのグレリンアンタゴニストの使用
ES2325773T5 (es) 2004-11-01 2014-02-24 Amylin Pharmaceuticals, Llc. Tratamiento de la obesidad y de los trastornos relacionados
US7187208B2 (en) * 2005-01-19 2007-03-06 Phaselink Semiconductor Corporation Complimentary metal oxide silicon low voltage positive emitter coupled logic buffer
US20090286723A1 (en) 2005-02-11 2009-11-19 Amylin Pharmaceuticals, Inc. Hybrid Polypeptides with Selectable Properties
US7737155B2 (en) 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
NZ562766A (en) 2005-05-30 2011-03-31 Banyu Pharma Co Ltd Piperidine derivatives as histamine-H3 receptor antagonists
US20090275648A1 (en) * 2005-06-13 2009-11-05 Fraser Graeme L Macrocyclic ghrelin receptor antagonists and inverse agonists and methods of using the same
EP1916239A4 (en) 2005-08-10 2009-10-21 Banyu Pharma Co Ltd PYRIDOLVERBINDUNG
BRPI0614649A2 (pt) 2005-08-11 2011-04-12 Amylin Pharmaceuticals Inc polipeptìdeos hìbridos com propriedades selecionáveis
AU2006282260A1 (en) 2005-08-24 2007-03-01 Msd K.K. Phenylpyridone derivative
US20090264426A1 (en) 2005-09-07 2009-10-22 Shunji Sakuraba Bicyclic aromatic substituted pyridone derivative
RU2427587C2 (ru) * 2005-09-28 2011-08-27 Ипсен Фарма С.А.С. Аналоги грелина
EP1928489B1 (en) 2005-09-28 2014-03-26 Ipsen Pharma Analogs of ghrelin
PT1937262T (pt) 2005-09-29 2019-08-21 Ipsen Pharma Sas Composição para utilização no tratamento de dismotilidade gastrointestinal
US8293900B2 (en) 2005-09-29 2012-10-23 Merck Sharp & Dohme Corp Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
EP1944301A4 (en) 2005-10-27 2012-01-04 Msd Kk NEW BENZOXATHIIN DERIVATIVES
CA2629018C (en) 2005-11-10 2013-12-31 Banyu Pharmaceutical Co., Ltd. Aza-substituted spiro derivative
US8992928B2 (en) 2006-02-11 2015-03-31 Victor Raso Isolated monoclonal antibody or antigen-binding fragment that cleaves octanoylated native ghrelin
US8088733B2 (en) 2006-07-06 2012-01-03 Tranzyme Pharma Inc. Methods of using macrocyclic agonists of the ghrelin receptor for treatment of gastrointestinal motility disorders
EP2698157B1 (en) 2006-09-22 2015-05-20 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
WO2008038692A1 (en) 2006-09-28 2008-04-03 Banyu Pharmaceutical Co., Ltd. Diaryl ketimine derivative
US8106086B2 (en) 2007-04-02 2012-01-31 Msd K.K. Indoledione derivative
EP2155227A4 (en) * 2007-05-14 2011-09-07 Abunon Ab NEW TREATMENT FOR DRUG DEPENDENCE
MX354786B (es) 2007-06-04 2018-03-21 Synergy Pharmaceuticals Inc Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos.
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
EP2264026A4 (en) 2008-03-06 2012-03-28 Msd Kk ALKYLAMINOPYRIDINDERIVATE
JPWO2009119726A1 (ja) 2008-03-28 2011-07-28 Msd株式会社 メラニン凝集ホルモン受容体拮抗作用を有するジアリールメチルアミド誘導体
CA2726917C (en) 2008-06-04 2018-06-26 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US20110071129A1 (en) 2008-06-19 2011-03-24 Makoto Ando Spirodiamine-diaryl ketoxime derivative
EP2321341B1 (en) 2008-07-16 2017-02-22 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
WO2010013595A1 (ja) 2008-07-30 2010-02-04 萬有製薬株式会社 5員-5員又は5員-6員縮環シクロアルキルアミン誘導体
US8410284B2 (en) 2008-10-22 2013-04-02 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
MX2011004551A (es) 2008-10-30 2011-05-25 Merck Sharp & Dohme Antagonistas del receptor de orexina de isonicotinamida.
CA2741672A1 (en) 2008-10-31 2010-05-06 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
WO2010075069A1 (en) 2008-12-16 2010-07-01 Schering Corporation Bicyclic pyranone derivatives as nicotinic acid receptor agonists
EP2379547A1 (en) 2008-12-16 2011-10-26 Schering Corporation Pyridopyrimidine derivatives and methods of use thereof
AU2010313282A1 (en) 2009-10-30 2012-05-24 Ocera Therapeutics, Inc. Macrocyclic ghrelin receptor antagonists and inverse agonists and methods of using the same
AU2011218830B2 (en) 2010-02-25 2014-07-24 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
CA2826649C (en) 2011-02-25 2016-07-26 Merck Sharp & Dohme Corp. Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
AR088352A1 (es) 2011-10-19 2014-05-28 Merck Sharp & Dohme Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina
US10039813B2 (en) 2012-02-07 2018-08-07 Massachusetts Institute Of Technology Use of antagonists of ghrelin or ghrelin receptor to prevent or treat stress-sensitive psychiatric illness
RU2015106909A (ru) 2012-08-02 2016-09-27 Мерк Шарп И Доум Корп. Антидиабетические трициклические соединения
BR112015019836A2 (pt) 2013-02-22 2017-07-18 Merck Sharp & Dohme composto, composição farmacêutica, e, uso de um composto
EP2970119B1 (en) 2013-03-14 2021-11-03 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
WO2014151200A2 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
JP2016514671A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼのアゴニストおよびその使用
WO2014144231A1 (en) 2013-03-15 2014-09-18 Massachusetts Institute Of Technology Use of antagonists of growth hormone or growth hormone receptor to prevent or treat stress-sensitive psychiatric illness
CN105764916B (zh) 2013-06-05 2021-05-18 博士医疗爱尔兰有限公司 鸟苷酸环化酶c的超纯激动剂、制备和使用所述激动剂的方法
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
AU2014331812B2 (en) 2013-10-09 2019-01-17 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for downregulation of pro-inflammatory cytokines
US9119832B2 (en) 2014-02-05 2015-09-01 The Regents Of The University Of California Methods of treating mild brain injury
MX389591B (es) 2014-08-29 2025-03-20 Tes Pharma S R L INHIBIDORES DE ACIDO A-AMINO-ß-CARBOXIMUCONICO SEMIALDEHIDO DESCARBOXILASA
WO2016138099A1 (en) 2015-02-24 2016-09-01 Massachusetts Institute Of Technology Use of ghrelin or functional ghrelin receptor agonists to prevent and treat stress-sensitive psychiatric illness
MX2019004321A (es) 2016-10-14 2019-06-12 Tes Pharma S R L Inhibidores de la acido alfa-amino-beta-carboximuconico semialdehido descarboxilasa.
US11072602B2 (en) 2016-12-06 2021-07-27 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
WO2018118670A1 (en) 2016-12-20 2018-06-28 Merck Sharp & Dohme Corp. Antidiabetic spirochroman compounds
CN118496217A (zh) 2018-11-20 2024-08-16 Tes制药有限责任公司 α-氨基-β-羧基己二烯二酸半醛去羧酶的抑制剂
EP3924058B1 (en) 2019-02-13 2026-01-07 Merck Sharp & Dohme LLC 5-alkyl pyrrolidine orexin receptor agonists
US12331018B2 (en) 2019-02-13 2025-06-17 Merck Sharp & Dohme Llc Pyrrolidine orexin receptor agonists
US12312332B2 (en) 2019-08-08 2025-05-27 Merck Sharp & Dohme Llc Heteroaryl pyrrolidine and piperidine orexin receptor agonists
US20230365533A1 (en) 2020-08-18 2023-11-16 Merck Sharp & Dohme Llc Bicycloheptane pyrrolidine orexin receptor agonists

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101693736B (zh) * 1999-07-23 2020-09-11 寒川贤治 新的肽
CA2411667A1 (en) * 2000-05-30 2001-12-06 Merck & Co. Inc. Ghrelin analogs

Similar Documents

Publication Publication Date Title
JP2004504406A5 (enExample)
ES2270335T7 (es) Composicion farmaceuta de efecto.
JP2004509061A5 (enExample)
JP2002526454A5 (enExample)
CA2661759A1 (en) Buprenophine-wafer for drug substitution therapy
MXPA03010731A (es) Combinacion de agonista del receptor a2a de adenosina y tiotropio o sus derivados para tratar enfermedades obstructivas de vias aereas.
CA2376978A1 (en) Compositions and methods for treatment of sexual dysfunction
JP2005520778A5 (enExample)
CA2440111A1 (en) Combinations comprising an antidiarrheal agent and an epothilone or an epothilone derivative
JP2004504406A (ja) グレリンアンタゴニスト
DE60327843D1 (de) Arzneimittelformulierungen mit verzögerter freisetzung mit einem trägerpeptid
JPH09507477A (ja) ヒドロキソコバラミンの鼻中投与用医薬組成物
JP2002524520A5 (enExample)
US20190209464A1 (en) Compositions, devices and methods for the treatment of alcohol use disorder
TW200836738A (en) Improvements in or relating to medicinal compositions
JP2002519425A5 (enExample)
JP2002528502A5 (enExample)
JP2006513184A5 (enExample)
JP2003519228A5 (enExample)
JP2007521244A5 (enExample)
CN101068571A (zh) 改善透粘膜给药制剂的吸收的方法
RU2003100507A (ru) Фармацевтические композиции
SK138095A3 (en) Transdermal therapeutic system for the administration of serotonin agonists
WO2004006929A1 (ja) 経鼻吸収用組成物
CA2492378A1 (en) Modified amino acid for the inhibition of platelet aggregation